Organogenesis Holdings Inc (NASDAQ:ORGO) Director Arthur S. Leibowitz Purchases 5,000 Shares

Organogenesis Holdings Inc (NASDAQ:ORGO) Director Arthur S. Leibowitz bought 5,000 shares of Organogenesis stock in a transaction dated Tuesday, September 3rd. The stock was purchased at an average cost of $4.20 per share, for a total transaction of $21,000.00. Following the purchase, the director now owns 5,000 shares of the company’s stock, valued at approximately $21,000. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.

Shares of ORGO traded up $0.76 during midday trading on Friday, hitting $5.40. The stock had a trading volume of 667,002 shares, compared to its average volume of 99,193. Organogenesis Holdings Inc has a 1 year low of $3.56 and a 1 year high of $310.90. The company has a current ratio of 1.51, a quick ratio of 1.14 and a debt-to-equity ratio of 3.78. The company’s 50 day moving average is $4.64.

Organogenesis (NASDAQ:ORGO) last announced its earnings results on Friday, August 9th. The company reported ($0.11) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.02. The firm had revenue of $64.95 million during the quarter, compared to analysts’ expectations of $61.00 million. Analysts predict that Organogenesis Holdings Inc will post -0.5 earnings per share for the current fiscal year.

Several equities research analysts have recently weighed in on ORGO shares. Credit Suisse Group started coverage on shares of Organogenesis in a research note on Monday, August 26th. They issued an “outperform” rating on the stock. BTIG Research set a $12.00 target price on shares of Organogenesis and gave the company a “buy” rating in a research note on Friday, August 9th. Finally, Zacks Investment Research downgraded shares of Organogenesis from a “hold” rating to a “sell” rating in a research note on Saturday, August 31st. One analyst has rated the stock with a sell rating and five have given a buy rating to the company. Organogenesis presently has a consensus rating of “Buy” and a consensus price target of $10.80.

Institutional investors and hedge funds have recently made changes to their positions in the company. Citadel Advisors LLC purchased a new stake in shares of Organogenesis in the second quarter valued at $200,000. Bank of New York Mellon Corp purchased a new position in Organogenesis in the 2nd quarter worth about $210,000. Northern Trust Corp increased its stake in Organogenesis by 134.3% in the 2nd quarter. Northern Trust Corp now owns 41,066 shares of the company’s stock worth $312,000 after buying an additional 23,540 shares during the period. Charles Schwab Investment Management Inc. increased its stake in Organogenesis by 36.6% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 86,495 shares of the company’s stock worth $658,000 after buying an additional 23,180 shares during the period. Finally, Moors & Cabot Inc. purchased a new position in Organogenesis in the 2nd quarter worth about $694,000. 1.60% of the stock is currently owned by institutional investors and hedge funds.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The company's advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types.

See Also: What does it mean to hold a stock in street name?

Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.